Meditation alters brain structure and function and influences epigenetic and telomere regulation, providing biological mechanisms that support its use as an alternative therapy for mental disorders, particularly major depressive disorder and substance-related and addictive disorders.
Ketamine's rapid antidepressant effects rely on the recruitment of TARP-γ8, a protein that regulates AMPA receptors, to postsynaptic sites in the ventral hippocampus of stressed male mice. Blocking TARP-γ8-containing AMPA receptors or uncoupling TARP-γ8 from PSD-95 abolished ketamine's rapid antidepressant effects. Overexpression of TARP-γ8 reversed chronic stress-induced depressive-like behaviors and reduced AMPA receptor-mediated neurotransmission, while knockdown of TARP-γ8 in excitatory neurons prevented ketamine's rapid effects. The findings suggest TARP-γ8 is a key molecular target for ketamine's antidepressant action.